Reasons for Nonadherence to Tamoxifen and Aromatase Inhibitors for the Treatment of Breast Cancer: A Literature Review

Suhila Sawesi, MSc, Janet S. Carpenter, PhD, RN, FAAN, and Josette Jones, PhD, RN



Despite improved breast cancer survival rates with the use of tamoxifen and aromatase inhibitors, patients remain at risk for cancer recurrence and mortality because of nonadherence to medication. The objective of this review was to identify factors associated with nonadherence among patients with breast cancer. Electronic databases were searched for studies, and potentially relevant studies were retrieved and assessed for eligibility. Potential factors associated with nonadherence were identified, and they included patient-related factors (e.g., patient beliefs and knowledge, fear of adverse effects, forgetfulness, smoking, age, race), therapy-related factors (e.g., duration,

side effects, additional prescribed medications, treatment interfering with lifestyle), healthcare system factors (e.g., patient/ provider relationships), socioeconomic factors (e.g., medication costs, burden, scheduling problems, religion, marital status), and disease-related factors (e.g., comorbidities, stage of breast cancer). Those findings highlight the need for development of interventions to promote long-term adherence in patients with breast cancer.

Suhila Sawesi, MSc, is a doctoral student in the Department of BioHealth Informatics in the School of Informatics, Janet S. Carpenter, PhD, RN, FAAN, is a professor, the Sally Reahard Chair, and director of the Center for Enhancing Quality of Life in Chronic Illness in the School of Nursing, and Josette Jones, PhD, RN, is an associate professor in the Department of BioHealth Informatics in the School of Informatics, all at Indiana University–Purdue University in Indianapolis. The authors take full responsibility for the content of the article. The authors did not receive honoraria for this work. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or editorial staff. Sawesi can be reached at ssawesi@umail.iu.edu, with copy to editor at CJONEditor@ons.org. (Submitted June 2013. Revision submitted August 2013. Accepted for publication September 7, 2013.)

Key words: breast cancer; chemotherapy; informatics and electronic health records; patient/public education; tamoxifen; aromatase inhibitors Digital Object Identifier: 10.1188/14.CJON.E50-E57

reast cancer is the most prevalent type of cancer among women worldwide (World Health Organization, 2014). Treatment commonly includes estrogensuppressive or ablative medications. Two types of hormone-based therapies (i.e., tamoxifen [TAM] and aromatase inhibitors [AIs]) have been shown to decrease disease recurrence and mortality rates (Nekhlyudov, Li, Ross-Degnan, & Wagner, 2011). TAM works by inhibiting estrogen action, and AIs work by inhibiting the aromatase enzyme-mediated peripheral conversion of androgen to estrogen (Johnston & Dowsett, 2003). TAM is used to treat pre-, peri-, or postmenopausal women with hormone receptor-positive breast cancer, and AIs are used to treat postmenopausal women with hormone receptor-positive breast cancer (van Herk-Sukel et al., 2010).

TAM and AIs have the potential to provide significant levels of clinical benefit if patients adhere to the regimens for the prescribed time period, which is usually a number of years. However, many women with breast cancer do not follow the protocol. Intentional and unintentional nonadherence to therapies persists and undermines the effectiveness of those therapies (Sedjo & Devine, 2011). Many patients with chronic diseases rarely follow their medication regimens, including patients with cancer who may be regarded as highly motivated because of the clinical consequences associated with nonadherence to the medication (Chlebowski & Geller, 2006). Healthcare providers should encourage women with breast cancer to adhere to the recommended dosage of TAM or AI at prescribed times each day and over the recommended time period. Randomized placebo-controlled